Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.
about
Application of Arterial Spin Labelling in the Assessment of Ocular TissuesThe Human Experience with Intravenous LevodopaMagnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's DiseaseOn the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publicationsPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesThe pediatric template of brain perfusion.Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).Applications of arterial spin labeled MRI in the brain.Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.Preclinical jockeying on the translational track of adenosine A2A receptors.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseCardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumorsProlactin and fMRI response to SKF38393 in the baboon.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Adenosine A2A antagonists in Parkinson's disease: what's next?Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Moonlighting adenosine deaminase: a target protein for drug development.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.A perfusion MRI study of emotional valence and arousal in Parkinson's disease.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.New and emerging medical therapies in Parkinson's disease.Orthostatic stability with intravenous levodopaAdditive global cerebral blood flow normalization in arterial spin labeling perfusion imaging.The effect of black tea and caffeine on regional cerebral blood flow measured with arterial spin labelingRapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle.Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI.Altered pallido-pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease.Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.In vitro pharmacological profile of the A2A receptor antagonist istradefylline.
P2860
Q26749327-D8F87D0C-DD06-4B2D-B625-1832AF2F6509Q26771516-4A8C10B8-87AB-4BEC-BBFE-FF6A3D6C3DAAQ26802087-B2BED31C-6512-4572-9976-86F4DA78D14CQ26998021-A7D0F1C3-8636-4699-BD13-8695F49C2DFCQ28088705-3438949B-A802-4253-9B76-42145C174EF6Q28648287-B679A10B-2E10-4E2A-BBEB-05484B1D0094Q33831798-1A18D5A4-B4F3-4FFD-85CF-B09219398D64Q34128055-A2B7632F-B841-4626-BC49-DFD1C5D8A1F2Q34533895-75525628-8D2F-4626-AD3B-3B2FB84C5FF3Q34777609-1AB573F2-7C8A-454C-8838-E5FE539AF137Q35489240-F0C1462A-1EF1-40A9-8AEA-BDCD93623B0FQ35614156-B4003964-B69E-499D-9AE8-FE5819B6FD72Q36057652-06F396CA-D8D3-4FF1-BC0B-2B183D4C8ABDQ36165527-A3692E95-EC8B-4876-97A3-A8E169BCA551Q37157425-2B29FA56-66C2-4302-B9FE-4B92C7A6B4ABQ37279952-98422790-3832-42F5-B6B6-A548DFA04691Q37506507-A0245E01-A093-4B78-92B3-A53B52DB2433Q37844573-1A4D315C-24C0-4470-99C8-07F18C9D2EE8Q37974709-249EA572-AFBC-43EF-A3B5-444A9E076F82Q38010070-F89BC015-2427-4797-B601-1FFD4D0138C1Q38022265-D468DC7F-5115-45CB-B9CD-92FD8ACD76B4Q38099828-98C41351-39DB-48F6-A9AE-FC87EE129B10Q38199744-DDA5862C-1DB3-426E-812B-2DA755A8879DQ38200930-B7E33D4D-3056-4B9E-8E44-F22C2C942FFAQ38220597-9E3035B4-A2E9-420C-A583-751F2F458D53Q38395423-19B64809-6331-43ED-AA18-DDF7C6C3354FQ38586316-A0E4FC90-65ED-4A1B-9EC7-48150BBDD9F7Q38658203-FDFD5B87-5DC4-460F-AA0B-D40DD7BE9BC9Q38718194-265054F2-2AD4-447B-81D7-37C483A18F34Q40577673-84869048-C3DE-4423-A959-BB5864F36CD7Q42143083-28C0D237-A74C-44F6-9B07-F7878EBC4879Q42146489-1CC971D1-C5E6-4F52-B54F-A7E2FA553C16Q42549573-B6511C55-28CA-4DE5-BEE4-B46FC124B164Q42656092-133FFCE4-06D4-433C-B1C0-2AFDAAECB073Q48410011-7FD3519D-810F-41AE-887A-BFB5E52B35A6Q48956010-C5BE568D-FCD0-4DA1-9F0F-E0771C2E3DC5Q50868357-9725E776-10BC-4728-B217-C4132CD2AEAB
P2860
Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@ast
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@en
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@nl
type
label
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@ast
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@en
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@nl
prefLabel
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@ast
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@en
Quantification of indirect pat ...... t SYN115 in Parkinson disease.
@nl
P2093
P2860
P1476
Quantification of indirect pat ...... st SYN115 in Parkinson disease
@en
P2093
Debra A Gusnard
Jonathan M Koller
Stephen I Bandak
P2860
P304
16284-16292
P356
10.1523/JNEUROSCI.2590-10.2010
P407
P577
2010-12-01T00:00:00Z